1984 Volume 32 Issue Supplement9 Pages 254-263
AC-1370, a cephem antibiotic developed in Japan, has a broad antibacterial spectrum, and potent antibacterial activities especially against gram-negative rods, including Pseudomonas aeruginosa. When one patient with cystitis was given 1 g of AC-1370 by intravenous one-shot injection, the level of the agent in the blood was 83.0 μg/ml in hour, 16.8μg/ml in 6 hours, and 11.1μg/ml in 8 hours, with such a long halflife as 3.06 hours.
A total of 15 patients, made up of 6 with pneumonia, another with diffuse panbronchiolitis, another with infection as a complication of pulmonary emphysema, 4 with acute pyelonephritis, another with urinary tract infection, and the other 2 with biliary infections, were given 1g of AC-1370 2 or 3 times daily, for 7 to 31 consecutive days.
Seven of the 8 patients with respiratory tract infections and 4 of the 5 with urinary tract infections showed a “good” to “excellent” response, and both of the 2 patients with biliary tract infections, a “good” response to the treatment.
Rashes were clinically observed as a side effect of the agent in one; and laboratory studies revealed an elevation of GOT and GPT in one and eosinophilia in another of the patients.
From these findings, AC-1370 may be said to be one of the clinically useful cephem antibiotics.
